STAGE IV RENAL CELL CANCER AJCC V8
Clinical trials for STAGE IV RENAL CELL CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV RENAL CELL CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV RENAL CELL CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental cocktail aims to reboot immune attack on tough cancers
Disease control TerminatedThis early-phase study tested a drug called plinabulin combined with radiation and immunotherapy in 19 people with advanced cancers (like lung, bladder, or melanoma) that had stopped responding to standard immunotherapy. The goal was to see if the combination was safe and could s…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:15 UTC
-
New drug combo tested for advanced kidney cancer – study stopped early
Disease control TerminatedThis study tested a combination of two drugs, sitravatinib and nivolumab, in 15 people with advanced kidney cancer that had spread and worsened after prior treatments. The goal was to see if the combo could shrink tumors or slow the disease. The study was terminated early, so res…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
Immune booster before kidney surgery shows promise but study halted
Disease control TerminatedThis study looked at giving the immunotherapy drug pembrolizumab (with or without axitinib) to people with advanced kidney cancer before they had surgery to remove the tumor. The goal was to see if this approach could increase immune cells in the tumor and help control the cancer…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
Immunotherapy duo tried against rare kidney cancer – trial halted early
Disease control TerminatedThis study tested a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 10 people with a rare and aggressive kidney cancer called renal medullary carcinoma. The goal was to see if the drugs could shrink tumors or slow cancer growth. The trial was terminated early…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 18, 2026 12:13 UTC